Investors Face Deadline in PROCEPT BioRobotics Securities Lawsuit

The legal action, filed by Levi & Korsinsky, LLP, centers on allegations that PROCEPT misled the market by attributing revenue fluctuations to external factors like saline shortages while failing to disclose a persistent 8% to 16% gap between handpiece shipments and actual AquaBeam procedures. These discrepancies allegedly hid an inventory buildup of over 10,000 field handpieces, artificially inflating the company's valuation.

Wall Street scrutiny intensified following a February 25, 2026, disclosure that revealed the true state of procedure demand and a 30% sequential contraction in unit sales. Analysts had previously relied on these sales figures to gauge the company's growth, assuming they mirrored recurring clinical use. Joseph E. Levi, representing the firm, noted that the core issue rests on whether investors were misled by incomplete disclosures regarding customer inventory levels. Shares, which reached highs of approximately $100.00 during the class period, subsequently dropped to below $25.00 following the revelations.